Engineering immune cells to outsmart Leukemia's defenses

NCT ID NCT07743047

Not yet recruiting Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study investigates how to engineer T cells to more effectively target acute myeloid leukemia (AML). Researchers will analyze samples from healthy donors and AML patients to identify T-cell receptors that recognize leukemia cells. The goal is to create next-generation engineered T cells with enhanced anti-leukemic activity, potentially leading to improved treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Engineered T cells with novel T-cell receptors (TCRs)
What this could lead to: If successful, this research could lead to more effective T-cell therapies for acute myeloid leukemia, potentially improving outcomes for patients.
What could go wrong: This is an early-stage laboratory study, so the engineered T cells may not prove safe or effective in humans. The findings may not translate into a practical treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.